Physician Agency and Competition: Evidence from a Major Change to Medicare Chemotherapy Reimbursement Policy
NBER Working Paper No. 19247
---- Acknowledgements -----
Mary Price provided excellent programming to create the original cohort used in this work. We thank Ernie Berndt, Srikanth Kadiyala, Emmett Keeler, David I. Levine, Tom McGuire, Giuseppe Ragusa, Heather Royer, James P. Smith, Tim Vogelsang and seminar participants at USC’s Sol Price School of Public Policy and the NBER Spring Health Care Program meetings for many helpful comments. Support for this analysis was made possible by grants from the Robert Wood Johnson Foundation’s Changes in Health Care Financing and Organization (HCFO) program and the National Cancer Institute, 1R01CA152043-01. All remaining errors are our own. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.
---- Disclosure of Financial Relationships for Joseph P. Newhouse -----
Newhouse is a director of, and holds equity in, Aetna, a health insurer.